MA38485A1 - Anticorps anti-cd52 humains pour une utilisation dans le traitement, par exemple, des maladies auto-immunes, le cancer, et le rejet de greffe - Google Patents

Anticorps anti-cd52 humains pour une utilisation dans le traitement, par exemple, des maladies auto-immunes, le cancer, et le rejet de greffe

Info

Publication number
MA38485A1
MA38485A1 MA38485A MA38485A MA38485A1 MA 38485 A1 MA38485 A1 MA 38485A1 MA 38485 A MA38485 A MA 38485A MA 38485 A MA38485 A MA 38485A MA 38485 A1 MA38485 A1 MA 38485A1
Authority
MA
Morocco
Prior art keywords
antibodies
cancer
autoimmune diseases
transplant rejection
human anti
Prior art date
Application number
MA38485A
Other languages
English (en)
Inventor
Huawei Qiu
Ronnie Rong Wei
Clark Qun Pan
Rebecca Sendak
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50391542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38485(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MA38485A1 publication Critical patent/MA38485A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des anticorps anti-cd52 humains et les fragments de liaison à l'antigène de ceux-ci. L'invention concerne aussi des acides nucléiques isolés, des vecteurs recombinés et des cellules hôtes pour fabriquer des anticorps et des fragments. Les anticorps et les fragments peuvent être utilisés dans des applications thérapeutiques pour traiter, par exemple, des maladies auto-immunes, le cancer, et le rejet de greffe.
MA38485A 2013-03-15 2014-03-13 Anticorps anti-cd52 humains pour une utilisation dans le traitement, par exemple, des maladies auto-immunes, le cancer, et le rejet de greffe MA38485A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361794576P 2013-03-15 2013-03-15
PCT/US2014/026159 WO2014151644A2 (fr) 2013-03-15 2014-03-13 Anticorps anti-cd52

Publications (1)

Publication Number Publication Date
MA38485A1 true MA38485A1 (fr) 2017-06-30

Family

ID=50391542

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38485A MA38485A1 (fr) 2013-03-15 2014-03-13 Anticorps anti-cd52 humains pour une utilisation dans le traitement, par exemple, des maladies auto-immunes, le cancer, et le rejet de greffe

Country Status (36)

Country Link
US (2) US9708407B2 (fr)
EP (1) EP2970467B1 (fr)
JP (2) JP6482524B2 (fr)
KR (1) KR20150131286A (fr)
CN (1) CN105209495B (fr)
AR (1) AR095199A1 (fr)
AU (1) AU2014233685B2 (fr)
BR (1) BR112015022464A2 (fr)
CA (1) CA2906539A1 (fr)
CL (1) CL2015002705A1 (fr)
CR (1) CR20150547A (fr)
CY (1) CY1121795T1 (fr)
DK (1) DK2970467T3 (fr)
DO (1) DOP2015000211A (fr)
EA (1) EA031730B1 (fr)
ES (1) ES2710976T3 (fr)
GT (1) GT201500267A (fr)
HK (1) HK1219963A1 (fr)
HR (1) HRP20190085T1 (fr)
HU (1) HUE041796T2 (fr)
IL (1) IL241410A0 (fr)
LT (1) LT2970467T (fr)
MA (1) MA38485A1 (fr)
MX (1) MX2015012991A (fr)
NZ (1) NZ631473A (fr)
PE (1) PE20151757A1 (fr)
PH (1) PH12015501932A1 (fr)
PL (1) PL2970467T4 (fr)
PT (1) PT2970467T (fr)
SG (1) SG11201506932SA (fr)
SI (1) SI2970467T1 (fr)
TN (1) TN2015000415A1 (fr)
TR (1) TR201900638T4 (fr)
TW (1) TWI644923B (fr)
UY (1) UY35440A (fr)
WO (1) WO2014151644A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101537840B1 (ko) 2009-05-13 2015-07-22 젠자임 코포레이션 항-인간 ｃｄ52 면역글루불린
AU2010248935B2 (en) 2009-05-13 2016-12-15 Genzyme Corporation Methods and compositions for treating lupus
EP3079322B1 (fr) * 2014-01-28 2020-06-10 Huawei Technologies Co., Ltd. Procédé d'indication de transmission de données, point d'accès et terminal
TW201841653A (zh) * 2017-04-21 2018-12-01 美商建新公司 以抗-cd52抗體治療多發性硬化症
JP2021513540A (ja) * 2018-02-13 2021-05-27 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法
WO2021022044A1 (fr) * 2019-07-31 2021-02-04 Forty Seven, Inc. Régimes d'appauvrissement pour une thérapie à lymphocytes t ou à cellules nk modifiés
TW202413407A (zh) * 2022-08-15 2024-04-01 國立大學法人東京大學 使用絲狀真菌之免疫球蛋白或多聚體免疫球蛋白之製造方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3783588T2 (de) 1986-04-17 1993-06-09 Kyowa Hakko Kogyo Kk Neue verbindungen dc-88a und dc-89a1 und deren herstellungsverfahren.
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2598116B2 (ja) 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
JP2510335B2 (ja) 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9108056D0 (en) 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
EP0519596B1 (fr) 1991-05-17 2005-02-23 Merck & Co. Inc. Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
CA2103059C (fr) 1991-06-14 2005-03-22 Paul J. Carter Methode de production d'anticorps humanises
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5269388A (en) 1991-11-12 1993-12-14 Stress-Tek, Inc. Weighing bed
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
WO1994026087A2 (fr) 1993-05-14 1994-11-24 Connor Kim C O Production de proteines de recombinaison, culture de cellules d'insectes et procede s'y rapportant
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
ES2220927T3 (es) 1994-04-22 2004-12-16 Kyowa Hakko Kogyo Co., Ltd. Derivados de dc-89.
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
EP1051432B1 (fr) 1998-12-08 2007-01-24 Biovation Limited Modification de l'immunogenicite de proteines
ES2276708T3 (es) 1999-11-24 2007-07-01 Immunogen, Inc. Agentes citotoxicos que comprenden taxanos y su uso terapeutico.
GB2361704C (en) 2000-03-03 2006-08-02 Cambridge Antibody Tech Human antibodies against eotaxin and their use
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
WO2003048731A2 (fr) 2001-12-03 2003-06-12 Abgenix, Inc. Categorisation d'anticorps reposant sur des caracteristiques de liaison
EP3960855A1 (fr) 2001-12-28 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Procédé de stabilisation de protéines
WO2003074679A2 (fr) 2002-03-01 2003-09-12 Xencor Optimisation d'anticorps
US20050191632A1 (en) 2002-11-01 2005-09-01 John Byrd Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
CN1225480C (zh) 2002-12-18 2005-11-02 马菁 抗cd52单克隆抗体、其编码序列及应用
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
WO2004087210A1 (fr) 2003-03-31 2004-10-14 Kirin Beer Kabushiki Kaisha Methode d'induction de differenciation et de proliferation de cellules t regulatrices par un anticorps anti-cd52 et composition medicinale associee
US7709224B2 (en) 2003-06-03 2010-05-04 Biosante Pharmaceuticals, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
CN1898267B (zh) 2003-11-01 2012-05-23 默克专利股份有限公司 修饰的抗cd52抗体
US20060204496A1 (en) 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
AP2007004250A0 (en) 2005-05-24 2007-12-31 Avestha Gengraine Tech Pvt Ltd Recombinant method for the production of a monoclonal antibody to cd52 for the treatment of chronic lymphocytic leukemia
LT2460831T (lt) * 2005-05-27 2016-12-12 Biogen Ma Inc. Tweak rišantys antikūnai
JP2009521909A (ja) 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ＩＬ−６とＩＬ−６Ｒαの複合体のｇｐ１３０への結合を阻害する抗ＩＬ−６抗体
EP2380585B1 (fr) 2006-04-12 2015-07-08 Genzyme Corporation Procédés de traitement des maladies auto-immunes
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
HUE026740T2 (en) 2006-09-13 2016-07-28 Alcafleu Man Gmbh & Co Kg Treatment of Multiple Sclerosis (MS) with Campath-1H
EP2417974A1 (fr) * 2007-02-28 2012-02-15 Schering Corporation Polythérapie pour le traitement de maladies immunes
CA2689408A1 (fr) 2007-06-22 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Utilisation d'anticorps diriges contre l'antigene cd52 pour le traitement de troubles neurologiques, en particulier l'encephalopathie spongiforme transmissible et la maladie d'alzheimer
EP2429584A4 (fr) 2009-05-13 2013-02-20 Genzyme Corp Procédés et compositions de traitement
AU2010248935B2 (en) 2009-05-13 2016-12-15 Genzyme Corporation Methods and compositions for treating lupus
KR101537840B1 (ko) * 2009-05-13 2015-07-22 젠자임 코포레이션 항-인간 ｃｄ52 면역글루불린
CN105440133A (zh) * 2009-07-15 2016-03-30 Aimm医疗股份公司 革兰氏阳性细菌特异性结合化合物
CN105734678B (zh) * 2010-07-16 2019-11-05 阿迪马布有限责任公司 合成多核苷酸文库

Also Published As

Publication number Publication date
MX2015012991A (es) 2015-12-15
PH12015501932A1 (en) 2016-01-04
PL2970467T3 (pl) 2019-07-31
AR095199A1 (es) 2015-09-30
SG11201506932SA (en) 2015-09-29
JP2019069960A (ja) 2019-05-09
US9708407B2 (en) 2017-07-18
KR20150131286A (ko) 2015-11-24
PE20151757A1 (es) 2015-12-03
DOP2015000211A (es) 2015-11-30
TN2015000415A1 (en) 2017-01-03
US20170349665A1 (en) 2017-12-07
CA2906539A1 (fr) 2014-09-25
LT2970467T (lt) 2019-02-11
CL2015002705A1 (es) 2016-04-22
CR20150547A (es) 2016-01-08
EP2970467A2 (fr) 2016-01-20
TR201900638T4 (tr) 2019-03-21
UY35440A (es) 2014-10-31
EA201591796A1 (ru) 2016-01-29
HRP20190085T1 (hr) 2019-03-08
PL2970467T4 (pl) 2019-07-31
AU2014233685B2 (en) 2019-02-28
WO2014151644A2 (fr) 2014-09-25
BR112015022464A2 (pt) 2017-10-24
TW201522373A (zh) 2015-06-16
ES2710976T3 (es) 2019-04-29
CY1121795T1 (el) 2020-07-31
IL241410A0 (en) 2015-11-30
HUE041796T2 (hu) 2019-05-28
AU2014233685A1 (en) 2015-10-01
JP2016518333A (ja) 2016-06-23
EA031730B1 (ru) 2019-02-28
EP2970467B1 (fr) 2018-10-17
WO2014151644A3 (fr) 2015-01-15
TWI644923B (zh) 2018-12-21
GT201500267A (es) 2017-12-15
PT2970467T (pt) 2019-01-28
CN105209495B (zh) 2020-06-26
DK2970467T3 (en) 2019-02-11
US20160024219A1 (en) 2016-01-28
CN105209495A (zh) 2015-12-30
JP6482524B2 (ja) 2019-03-13
HK1219963A1 (zh) 2017-04-21
NZ631473A (en) 2017-09-29
SI2970467T1 (sl) 2019-03-29

Similar Documents

Publication Publication Date Title
MA38485A1 (fr) Anticorps anti-cd52 humains pour une utilisation dans le traitement, par exemple, des maladies auto-immunes, le cancer, et le rejet de greffe
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
EA202090817A1 (ru) Триспецифические белки и способы их применения
EA201992063A1 (ru) СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1
PH12016502590B1 (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MA38478A1 (fr) Anticorps anti-pac1 humains
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
EA201590941A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
MA41596A (fr) Anticorps anti-tau et leurs utilisations
IN2014CN04645A (fr)
MA39342B2 (fr) Anticorps il -21
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
EA202090372A1 (ru) Универсальные соединения авт и их применение
MX2019015071A (es) Composiciones y metodos para tratar tauopatias.
MX2017012397A (es) Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
MX2018009499A (es) Anticuerpos monoclonales especificos de egfl6 y metodos de su uso.
EA202192488A1 (ru) Антитела против tsg-6 и их применения